Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members see a lot more than you) LoginRegister
Psoriasis Club is a friendly on-line Forum where people with psoriasis or psoriatic arthritis
can get together and share information, get the latest news, or just chill out with others who understand. It is totally
self funded and we don't rely on drug manufacturers or donations. We are proactive against Spammers,
Trolls, And Cyberbulying and offer a safe friendly atmosphere for our members.
So Who Joins Psoriasis Club?
We have members who have had psoriasis for years and some that are newly diagnosed. Family and friends of those with psoriasis
are also made welcome. You will find some using prescribed treatments and some using the natural approach. There are people who
join but keep a low profile, there are people who just like to help others, and there are some who just like
to escape in the Off Topic Section.
Joining Couldn't Be Easier: If you are a genuine person who would like to meet others who understand,
just hit the Register button and follow the instructions.
Members get more boards and privileges that are not available to guests.
OK So What Is Psoriasis?
Psoriasis is a chronic, autoimmune disease that appears on the skin. It
occurs when the immune system sends out faulty signals that speed up the
growth cycle of skin cells. Psoriasis is not contagious. It commonly
causes red, scaly patches to appear on the skin, although some patients
have no dermatological symptoms. The scaly patches commonly caused by
psoriasis, called psoriatic plaques, are areas of inflammation and
excessive skin production. Skin rapidly accumulates at these sites which
gives it a silvery-white appearance. Plaques frequently occur on the
skin of the elbows and knees, but can affect any area including the
scalp, palms of hands and soles of feet, and genitals. In contrast to
eczema, psoriasis is more likely to be found on the outer side of the
joint.
The disorder is a chronic recurring condition that varies in severity
from minor localized patches to complete body coverage. Fingernails and
toenails are frequently affected (psoriatic nail dystrophy) and can be
seen as an isolated symptom. Psoriasis can also cause inflammation of
the joints, which is known as (psoriatic arthritis). Ten to fifteen
percent of people with psoriasis have psoriatic arthritis.
The cause of psoriasis is not fully understood, but it is believed to
have a genetic component and local psoriatic changes can be triggered by
an injury to the skin known as Koebner phenomenon. Various
environmental factors have been suggested as aggravating to psoriasis
including stress, withdrawal of systemic corticosteroid, excessive
alcohol consumption, and smoking but few have shown statistical
significance. There are many treatments available, but because of its
chronic recurrent nature psoriasis is a challenge to treat. You can find more information
Here!
Got It, So What's The Cure?
Wait Let me stop you there! I'm sorry but there is no cure. There are things that can help you
cope with it but for a cure, you will not find one.
You will always be looking for one, and that is part of the problem with psoriasis There are people who know you will be
desperate to find a cure, and they will tell you exactly what you want to hear in order to get your money. If there is a
cure then a genuine person who has ever suffered with psoriasis would give you the information for free. Most so called cures
are nothing more than a diet and lifestyle change or a very expensive moisturiser. Check out the threads in
Natural Treatments first and save your money.
Great so now what? It's not all bad news, come and join others at Psoriasis Club and talk about it. The best help is from accepting it and talking
with others who understand what you're going through. ask questions read through the threads on here and start claiming
your life back. You should also get yourself an appointment with a dermatologist who will help you find something that can
help you cope with it. What works for some may not work for others
Skilerance is a great drug and works but the side affects for me on 120 mg is not bearable. I've tried it with food and yogurt,I've even cut the tablet in half and hid it in a soft sweet and swallowed half in the morning and half late afternoon but the cramps i get and sweats and going red is crazy. I need to inform my dermatologist but after being on methotrexate and cyclosporine, I don't now what other options I have. Any suggestions would be welcome as i'm sure you all know how i'm feeling.
Hi.. Ive been search this place and also the inspire page in the US and although GI / diarrhea is a listed side effect there doesnt seem much else on it: Novartis is stating it cannot cause IBD... it can only bring it on if the person had it already but I have seen one person on this page and another in the US who did not have it before, and do have it now.
I think I fall into this category... the pain started on my second monthly dose after the 5 loading doses...I was doing really well until then and the GI issues were severe: severe diarrhea for a week with severe cramping.. this lasted a month, now I am on anti ulcer meds which help a little with pain but the pain was across the whole system from stomach down to colon. though mostly upper.
Am waiting for tubes and cameras but the wait list is a while! ... has anyone else experienced this? They are suggestingI change to a different biologic but I am quite worried about trying something new now.... I basically lost a month of my life lying in bed or running to the loo!
Posted by: KatT - Mon-23-09-2019, 06:22 AM
- Replies (14)
Hi!
Found this site while browsing for information on biologics. I have been diagnosed with plaque psoriasis , which is hereditary in my family, 25 years ago and psoriatic arthritis (the first in the family) 10 years ago. Wow, writting this down makes me feel old!
Started on biologics 2 years ago because of the arthritis. I was tired of being in pain. Still am!
I am on Cosentyx which pretty much cleared up my psoriasis but my rheumatologist just increased the dose as it wasn't doing anything for the arthritis. Hope it works!
Posted by: Fred - Sat-21-09-2019, 15:40 PM
- Replies (31)
Figures vary on how many people with psoriasis will go on to get psoriatic arthritis but it is around 1/4.
Psoriatic arthritis (PsA)
• When joints are inflamed they become tender, swollen and painful on movement.
• Joints are typically stiff after resting, early morning or resting in the evening.
• Tissues such as ligaments, tendons around the joints may be involved.
• Inflammation of tendon or muscle (such as tennis elbow (Lateral Epicondylitis) and pain around the heel) is also a feature in those with psoriatic arthropathy.
• In approximately 80% of cases the arthritis develops after the appearance of psoriasis.
• In 20% of cases the joint inflammation comes first.
Joints normally function to allow movement to occur between bone ends, which are important for the body to move. Bone ends are covered with cartilage around which is a capsule lined by a membrane called synovium.
This membrane normally makes the fluid that lubricates the joint space allowing movement. In arthritis the synovial membrane becomes inflamed - and releases substances that cause inflammation.
The inflamed synovium releases more fluid than normal and so the joint becomes tender and swollen. Persistent inflammation may lead to damage to the cartilage and erosion of the underlying bone.
Synovial membrane also lines and lubricates tendons and so they become inflamed too.
There are several features that distinguish (PsA) from other forms of arthritis:
• Particular patterns of joints that may be involved.
• One pattern of inflammation is usually in the end joints of fingers often corresponding with the fingers that have psoriatic nail involvement, which is more common in men than women.
• Another pattern is involvement of the joints of the spine and sacroiliac joints which is called spondylitis similar to ankylosing spondylitis.
• Neck pain and stiffness.
• An entire toe or finger can become swollen or inflamed which is termed dactylitis.
• There is a tendency for joints to stiffen up and sometimes to fuse together.
• Importantly the absence of rheumatoid factor in the blood helps distinguish psoriatic arthritis from rheumatoid arthritis.
• Distinguishing features are not always present and the individual may have swelling of a few or many joints that is similar to other types of arthritis making diagnosis difficult.
In 80% of individuals with arthritis, psoriatic nail changes are found, which is more common than with psoriasis alone.
Nail changes include pitting, discolouration of the nail due to abnormalities in the growth of tissue in the nailbed.
The risk of developing arthritis is greater in individuals with severe psoriasis, yet occasionally severe arthritis may occur with minimal skin disease.
The above is taken from this thread Types Of Psoriasis Explained we also have other threads, but we don't have a thread dedicated to psoriatic arthritis. So I will make this a sticky thread so it easy to find.
All members are welcome to post their experiences, questions or suggestions for this first post. All I ask is that we keep on topic of just Psoriatic Arthritis.
Howdy - Currently on Cosentyx for 4 mo, generally feeling better yay!
But having sudden sharp mental decline. Can still recite and analyze passages from Chaucer and Shakespeare no prob (retired Engl Lit teacher) but cant remember to lock the front door when I go out, turn off the coffee pot, pay bills on time, and recently had a “spell” where I was driving to a dr’s appmnt, got confused, then lost, and ended up driving all over town for an afternoon - didnt know where I was going, or why, or where I was, or how to get home. I have lived in this same small town for 20 years!
Has anyone else experienced mental confusion while on Cosentyx? It is not listed as a side effect. Or could this be something else?
I’m not really a cowboy, it’s just an avatar. I’m really a middle aged urban Texan (having lived in NYC, LA, Wash DC, San Fran, as well as Houston and various DFW ‘burbs.), although I have Tx cred via various relatives. Diagnosed w psoriasis as a teen, and PsA at midlife. It ebbs and flows, and I am not entirely certain any of my meds are doing much to control it. So glad I found this forum, bc I don’t know anyone else who has it, that I can talk to, who understands.
Posted by: Fred - Wed-04-09-2019, 14:35 PM
- Replies (1)
This study evaluates the efficacy and safety of recommended Taltz (ixekizumab) dose over 4 years.
Quote:Background:
Psoriasis, a chronic disease usually requires long‐term disease management.
Objective:
This study evaluates the efficacy and safety of recommended ixekizumab (IXE) dose over 4 years (204 weeks) from UNCOVER‐3 study.
Methods:
UNCOVER‐3 was a randomized, double‐blind, multicenter, Phase 3 study wherein patients with moderate‐to‐severe plaque psoriasis received placebo, IXE 80 mg every 2 weeks (Q2W), IXE 80 mg every 4 weeks (Q4W) (both IXE groups had 160 mg starting dose), or etanercept 50 mg twice weekly. At Week 12, all patients switched to IXE Q4W dose for the long‐term extension (264 weeks). After Week 60 and at investigator's discretion, patients could receive dose adjustment to IXE Q2W. The efficacy endpoints at Week 204 were percentage of patients achieving PASI 75/90/100, sPGA score of 1 or 0, and those achieving PSSI=0, NAPSI=0, and PPASI 100. Efficacy data were summarized through 204 weeks using as‐observed, multiple imputation (MI), and modified nonresponder imputation (mNRI) methods.
Results:
The proportion of patients achieving PASI 75/90/100 at Week 204 using mNRI method were 82.8%, 66.4%, and 48.3%, respectively. Using as‐observed and MI methods, 98.2% and 94.8% patients achieved PASI 75, 87.8% and 73.3% achieved PASI 90, and 67.1% and 52.7% achieved PASI 100 response, respectively, at Week 204. The response rates for sPGA (0, 1) were 88.7%, 76.2%, 68.5% and for sPGA (0) were 68.9%, 54.6%, and 49.7% using as‐observed, MI, and mNRI methods, respectively. Similar trends were observed with NAPSI=0, PSSI=0, PPASI 100, and itch NRS=0. There were no new safety concerns through Year 4.
Conclusions:
This study demonstrated sustained high‐efficacy response through 4 years of continuous treatment with ixekizumab in patients with moderate‐to‐severe plaque psoriasis. The safety profile remained consistent with prior findings, with no new or unexpected safety concerns.
Posted by: Duncan - Sun-01-09-2019, 11:35 AM
- Replies (29)
Looks like another drug failed due to diarrhoea.
I tried Oteza. It was working but the longer I was on it, the worse my diarrhoea got.
I am now on Skilerence. Only got to 2x 120mg tablets a day. No will I get to 6 a day. Horrendous stomach pains at times, but the diarrhoea is now bad
Very limited what I can take due to high blood pressure
Posted by: Fred - Fri-30-08-2019, 11:53 AM
- Replies (2)
This study looked at quality of life outcomes in adults with moderate‐to‐severe plaque psoriasis treated with dimethylfumarate (DMF)
Quote:Background:
Psoriasis is a chronic inflammatory skin disease associated with quality of life (QoL) impairment. BRIDGE was a randomised, double‐blind, phase III study comparing the efficacy and safety of dimethylfumarate (DMF) with a fixed combination of fumaric acid esters (FAE) or placebo for the treatment of moderate‐to‐severe psoriasis.
Objectives:
This post‐hoc analysis investigated treatment effect on QoL overall and by patient sub‐groups categorised by disease severity. Week 8 efficacy responses were also investigated as possible predictors of Week 16 Dermatology Life Quality Index (DLQI) outcomes.
Methods:
Patients were randomised to receive a maximum daily dose of 720 mg of DMF, FAE (gradual up‐titration) or placebo for 16 weeks. Psoriasis Area Severity Index, Body Surface Area, Physician's Global Assessment and DLQI were assessed at baseline, Week 8 and 16. DLQI 0–1 indicated ‘no effect on patient life’. Associations between baseline severity,
Week 16 DLQI and Week 8 efficacy (as observed cases) were also examined.
Results:
At baseline, 671 patients were included in the full analysis set (267 randomised to DMF, 273 to FAE and 131 to placebo). DMF was superior to placebo (P < 0.001) and not significantly different to FAE regarding Week 16 DLQI outcomes (P > 0.05). Baseline disease severity did not impact DLQI outcomes at Week 16. In DMF‐ and FAE‐treated patients, Week 8 PASI 50/75 responders reported better DLQI responses at Week 16 vs non‐responders (P < 0.05). Week 8 PASI ≤3 and/or PGA 0–1 responders were also more likely to report DLQI 0–1 at Week 16 vs non‐responders (P < 0.05).
Conclusion:
DMF significantly improved DLQI outcomes versus placebo and was not affected by baseline disease severity. Efficacy responses (PASI 50/75, PASI ≤3 and PGA 0–1) as early as Week 8 were predictive of QoL outcomes at Week 16 in DMF‐ and FAE‐treated patients.
Posted by: Fred - Thu-22-08-2019, 12:41 PM
- Replies (3)
Following on from Skyrizi gets positive opinion from CHMP Skyrizi (risankizumab) has been given the go ahead from NICE (National Institute for Health and Care Excellence) in the treatment of moderate to severe plaque psoriasis.
Quote:
Risankizumab is recommended as an option for treating plaque psoriasis in adults, only if: The disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated and the company provides the drug according to the commercial arrangement.
Stop risankizumab treatment at 16 weeks if the psoriasis has not responded adequately. An adequate response is defined as:
A 75% reduction in the PASI score (PASI 75) from when treatment started or
A 50% reduction in the PASI score (PASI 50) and a 5‑point reduction in DLQI from when treatment started.
If patients and their clinicians consider risankizumab to be one of a range of suitable treatments, including guselkumab, secukinumab and ixekizumab, the least expensive should be chosen (taking into account administration costs, dosage, price per dose and commercial arrangements).
When using the PASI, healthcare professionals should take into account skin colour and how this could affect the PASI score, and make the clinical adjustments they consider appropriate.
When using the DLQI, healthcare professionals should take into account any physical, psychological, sensory or learning disabilities, or communication difficulties that could affect the responses to the DLQI and make any adjustments they consider appropriate.
These recommendations are not intended to affect treatment with risankizumab that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.
Why the committee made these recommendations:
Risankizumab is proposed as an alternative to other biological therapies already recommended by NICE for treating severe plaque psoriasis in adults. Evidence from clinical trials shows that risankizumab is more effective than adalimumab and ustekinumab. Indirect comparisons suggest that risankizumab is likely to provide similar health benefits compared with guselkumab, and better PASI response rates compared with many other biologicals.
For the cost comparison, it is appropriate to compare risankizumab with guselkumab. The total costs associated with risankizumab are similar to or lower than those associated with guselkumab. Therefore, risankizumab is recommended as an option for use in the NHS for severe plaque psoriasis that has not responded to systemic non-biological treatments, or if these are contraindicated or not tolerated.
Posted by: Fred - Sun-18-08-2019, 14:09 PM
- No Replies
Some of our members got together and decided the Dermatology Life Quality Index (DLQI) used by dermatologists didn't give a good representation of how psoriasis affects our daily life, so we decided to make our own version.
Psoriasis can have a huge impact on ones quality of life, and it is important to discuss with your dermatologist/doctor how it affects you. By keeping a score you will be able to see how your quality of life changes each month, this information can be helpful to monitor your treatment and to have some information for your next dermatology/doctor appointment.
Anyone can use it and members can add their score to their profile or keep a note of it in their personal notepad.
You can find it in the top menu next to the Pscore or just click here PQOLS
Posted by: Fred - Wed-14-08-2019, 13:40 PM
- No Replies
Lilly says that Taltz beats Tremfya in a head to head trial achieving skin clearance at week 12.
Quote:
Eli Lilly announced today Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA® (guselkumab) in people living with moderate to severe plaque psoriasis (PsO). The IXORA-R trial is the first completed head-to-head (H2H) trial between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as the primary endpoint.
At 12 weeks, Taltz met the primary endpoint by demonstrating superiority in the proportion of patients achieving complete skin clearance compared to TREMFYA as measured by PASI 100. In addition, Taltz met all major secondary endpoints up to week 12, which include superiority over TREMFYA in the proportion of patients achieving PASI 75 at Week 2, PASI 90 at Weeks 4 and 8, PASI 100 at Weeks 4 and 8, static Physician's Global Assessment (sPGA) 0 at Week 12 and PASI 50 at Week 1. Lilly plans to share results on the remaining key secondary endpoint of proportion of patients achieving PASI 100 at 24 weeks in 2020.
"Completely clear skin and rapid relief of symptoms are possible for many people living with moderate to severe plaque psoriasis, and should be two topics dermatologists discuss with their patients," said Andrew Blauvelt, M.D., M.B.A., dermatologist and president of Oregon Medical Research Center in Portland, OR. "Head-to-head data like these are important and will help inform individual treatment goal discussions between healthcare providers and their patients."
A total of 1,027 patients with moderate to severe plaque psoriasis were enrolled in the study to evaluate the efficacy and safety of Taltz compared to TREMFYA. Participants were randomized to receive Taltz (160 mg at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks) or TREMFYA (100 mg administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter) for a total of 24 weeks, with the primary analysis conducted at 12 weeks.
"Lilly's goal is to raise the treatment bar for people living with psoriasis," said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. "And research shows that patients want clear skin and rapid improvements. We're pleased to see that Taltz helped more people achieve 100 percent skin clearance compared to TREMFYA at week 12. These positive results reinforce that Taltz is an important treatment option for people with this disease."
In IXORA-R, the safety profile of Taltz was consistent with previously reported results. No new safety signals were detected.
Lilly plans to submit detailed data from the IXORA-R study for disclosure at scientific meetings and in peer-reviewed journals.
Posted by: Fred - Wed-14-08-2019, 12:51 PM
- No Replies
This study suggests patients unlikely to respond to Ilumya / Ilumetri (tildrakizumab) could be identified by week 8, and those likely to achieve a PASI >90 response could be identified as early as week 4.
Quote:Background:
Two randomized controlled trials (reSURFACE 1 and 2) have demonstrated the effectiveness of tildrakizumab, a high‐affinity, humanized, IgG1κ, anti‐interleukin‐23 monoclonal antibody, for treating moderate‐to‐severe plaque psoriasis in the first 28 weeks.
Objectives:
To examine the efficacy of tildrakizumab and its impact on quality of life (QoL) in patients with different levels of week‐28 Psoriasis Area and Severity Index (PASI) improvement.
Methods:
Patients treated with tildrakizumab 100 mg or 200 mg from baseline to week 28 were pooled from reSURFACE 1 and reSURFACE 2 and classified into five mutually exclusive week‐28 PASI improvement groups for each dose: PASI 0‐49, 50‐74, 75‐89, 90‐99, and 100. Mean PASI improvement and Dermatology Life Quality Index (DLQI) 0/1 over time were examined for each group.
Results:
Of 1,156 patients, 575 were in the 100‐mg and 578 in the 200‐mg cohorts, respectively. At week 28, 8.3%, 14.3%, 23.8%, 30.4%, and 23.1% in the 100‐mg and 4.0%, 18.1%, 19.6%, 29.1%, and 29.3% in the 200‐mg cohort achieved PASI <50, 50‐74, 75‐89, 90‐99, and 100, respectively. Patients with PASI <50 at week 28 could be identified as early as week 8, and those with week‐28 PASI ≥90 had approximately 50% PASI improvement by week 4. Among patients achieving PASI >50 at week 28 who continued the same dose of tildrakizumab to week 52, mean PASI improvement was maintained or improved over time. Similar results were observed for both doses. Higher proportions of patients achieved DLQI 0/1 in higher week‐28 PASI groups, and DLQI 0/1 was maintained or improved to week 52. However, not all patients with PASI 100 had DLQI 0/1.
Conclusion:
Patients unlikely to respond to tildrakizumab could be identified by week 8, and those likely to achieve a PASI >90 response could be identified as early as week 4. Week‐28 PASI improvement level correlated with QoL improvement.
Hello, I just joined the group a few minutes ago. I am so glad to have found this forum so I don't feel so alone now. I also have Multiple Sclerosis. With the MS and the psoriasis both being an autoimmune disease it complicates the way in which the psoriasis can be treated.
I am married and we have three children - all grown and 2 grandchilddren with the youngest graduating from high school this year. So this coming year they will both be in college. My husband and I are both retired. We sold our home a couple of years ago to downsize and are in an apartment at this time. We have not decided whether to stay in Raleigh, NC or move to another area. We really like the Ashville area but have lived in Raleigh for about 17 years now so I really don't know if I want to move to another area. It's harder after you get older to think about adjusting to a new place and having to find new doctors, dentist, church, etc. so we may just stay put.
My husband is a golfer and fly fisherman so he has really enjoyed being able to do both since retirement. I love any type of craft. I crochet, knit, and sew. I love to take old vintage linens. especially the white ones, and recycle them into new items. I also love to watch Turner Classic Movies. I prefer the old movies to the new ones. Much less violence and profanity.
That's pretty much my profile at this time and I look forward to being a part of the group.
Posted by: g137556s - Tue-13-08-2019, 00:07 AM
- Replies (10)
Hello All,
I have had Psoriasis in one form or another since I was about 5 years old. Back then, it was on my ankles. I went away after several years. Then in my early teens, I got it on my knees for several years before it went away. Then in my mid twenties I got it on my knuckles and have had it for several years. I am not 57 and about 4 years ago I started getting it on the side of one of my fingers and now the palm of my right had, unfortunately I am right handed. I have been dealing with it and hoping it would disappear after a couple of years but it has been getting larger and larger. Up until a few weeks ago the fold lines of my hand did not have plaques. But then they started getting it. Now my entire palm and the skin will crack in those folds. As some of y'all know, that is pretty painful. I cannot do much around the yard anymore because of it. Every time someone wants to shake my hand I really hate it. I really wish that social norm would just go away. So the past two weeks I started taing Glutamine and using Coal Tar.
Just joined. For years I've used the clear tape, hadn't had a flare up in years. I have small patches on my shoulder and arm and a different type on my elbows. the patches on my arm are red and raw and very itchy in this heat. I can't remember what they are called. I'm pretty sure antibiotics caused this bad flare up. I stopped taking them a couple weeks ago, just when this flare up started. I am currently trying cbd cream. I am here to read and learn.
Posted by: Arls2308 - Thu-08-08-2019, 02:37 AM
- Replies (15)
Hi there,
I am new but old here as in the last time I posed ( under a diff name ) was back in 2011. I have very bad guttate and plaque p which can cover up to 75% of my body. I have had this disease since I was 13- I’m 36 now.
I had been keeping my p under control for 8years with Fumaderm. I found it a wonder drug. I had the usual side affects but managed them by taking my full dose which was 8x 120 mg at night before bed. I would have very predicable flushes, cramps and “toilet rushes” in the morning and the rest of the day would be a clear skin pleasure. Exactly this time last year I fell pregnant whilst on Fumaderm _ planned / not planned but very welcomed and naturally had to come off Fumaderm. My skin flared badly and quickly. I had two lengthy sessions of light treatment to see me through what was otherwise a healthy pregnancy but as soon as I stopped, My skin flared massively again. Having returned to my dermatologist 6weeks post partum I’m now on skilarence. I turned down Sterala as I was so confident in Fumeric acid \ DMF . I’m now 6 weeks into treatment and I only see mild improvement. I’m also experiencing little or no side affects ... So much so that I actually went and tried some of my old stash of Fumaderm to see if it would work but little reaction to it as well.
I’m on 5x120 this week moving to 6x 120 next week. I expected to see a better result by now and wonder does the lack of side affects indicate that this time it’s not going to work for me
I’ll keep you updated as I move through this journey.
Thank you for the amazing content - this is an invaluable resource.
Posted by: Fred - Tue-06-08-2019, 21:03 PM
- Replies (7)
Probably a long shot but has anyone tried both Tremfya and Cosentyx for psoriatic arthritis ?
I'm very pleased with Cosentyx for the psoriatic arthritis and it is still in remission, but it's not keeping the psoriasis away and I still need the occasional use of a topical to keep it under control. I have decided Taltz is not worth me trying next, but am tempted to switch to Tremfya after reading this: Tremfya going after psoriatic arthritis
But there is nothing better than hearing it from the horses mouth so to speak, so has anyone tried both and if so which was best for psoriatic arthritis Tremfya or Cosentyx ?
I was prescribed the following and wondered if anyone has tried the same :-
Psoriderm cream 225ml
distilled coal tar 6% w/w
lecithin 0.4% w/w
(Use once or twice daily)
Psoriderm emulsion 40% w/v bath additive 200ml
distilled coal tar
(Use as needed)
Psoriderm scalp lotion shampoo 250ml
distilled coal tar 2.5% w/v
lecithin 0.3% w/v
(Use as a shampoo, daily if necessary)
I’ve had a pamper using all Psoriderm products today.
Not much to report as this is the first time I’ve ever used it (and found out I had psoriasis yesterday).
The packaging is nice. The bottles themselves are somewhat reminiscent of the 1940’s.
It stung a little in some areas as I applied it.
I smell. The house smells. Everything smells. I’ve made no attempt to get rid of the smell as of yet. I read in some other parts of the internet that using a strong smelling shampoo after masks said smell. Though I fear this could be counterintuitive.
I hope to update this thread with my progress as I go.
I’m new here. I’m not sure if I’m doing any of this right. Bare with me!
I don’t really have a history with psoriasis and the story of how I got here started yesterday when I was told by an Advanced Nurse Practitioner that the dandruff I have and the weird blotches I thought was ringworm and had been covering in anti-fungal cream are, in fact, psoriasis. (Woo! ) I deduced it was inverse psoriasis and scalp psoriasis.
I was prescribed Psoriderm cream, bath lotion and shampoo.
Had my first Psoriderm Pamper earlier today. (I was absolutely in the bath more than the recommended five minutes. Which is probably why it was starting to sting a little bit. Applying the cream to some parts stung too. Is this normal? Or the kind of not normal that people generally ignore and just carry on with?)
I smell. The house smells. My hair smellllllllllllllllllllls.
I have a date next week, how do I make it going away? Haha.
Worse still, I work for a large postal delivery service, let’s call it Moyal Rail. If it starts to rain, is the smell going to be even stronger?! Am I going to be the stinky postie?!
I started to google and came across this forum. I already can’t find the post I originally saw about Psoriderm. Ha. I’ll go through the history once I’ve managed to navigate the forum a bit better.
I have rambled far too much.
Hello! Thanks for letting me join. I will endeavour to scour the forum for advice on being less smelly and hopefully how to be more comfortable in and with my own body.
You have to register before you can post on our site.
Members Images
Join Psoriasis Club
Psoriasis Club is self funded, we don't rely on sponsorship or donations. We offer a safe
friendly forum and are proactive against spammers, trolls, and cyberbullying. Join us here!
No Advertising.
No Corprate Sponsors.
No Requests for Donations.
No Cyber-Bullying.
No Scams or Cures.
No Recruitment Posts.
No promotions or offers.
No Trolls.
No Spam.
Just a small bunch of friendly people with psoriasis sharing information and support.
Forum Statistics
» Members: 987 » Latest member: paul1961 » Forum threads: 7,144 » Forum posts: 261,426
There are currently 48 online users. »0 Member(s) | 47 Guest(s) "YOYO" The Psoriasis Club Bot Is On-line
Psoriasis Cure!
How many people have Psoriasis?
In 2012 there were approximately 36.5 million prevalent cases of psoriasis, and by 2022, GlobalData epidemiologists forecast that this figure will reach approximately 40.93 million.
The condition affects individuals of both sexes and all ethnicities and ages, although there is a higher prevalence of psoriasis in the colder, northern regions of the world.
The prevalence of psoriasis in the central region of Italy is 2.8 times greater than the prevalence in southern Italy.
Caucasians have a higher prevalence of psoriasis compared with African-Americans, but African-Americans in the US tend to suffer from a more severe form of the disease.